Athira Pharma Q2 EPS $(0.78) Beats $(0.79) Estimate
Portfolio Pulse from Benzinga Newsdesk
Athira Pharma reported Q2 losses of $(0.78) per share, beating the analyst consensus estimate of $(0.79) by 1.27 percent. However, this represents a 20 percent increase in losses compared to the same period last year.
August 10, 2023 | 9:06 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Athira Pharma's Q2 losses were less than expected, but increased compared to last year. This mixed result may lead to uncertain market reactions.
Athira Pharma's earnings beat estimates, which is generally positive for the stock. However, the increase in losses compared to the same period last year is a negative factor. These mixed results make the short-term impact on the stock uncertain.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100